Fibula Fracture
Conditions
Brief summary
The objective of this post-market clinical study is to evaluate efficacy outcomes and complication rates in patients who have received the Fibulock™ Intramedullary Nail.
Detailed description
This is a retrospective/prospective, multi-site observational study, designed to evaluate the clinical outcomes and complication rates in subjects who were previously implanted with a Fibulock™ intramedullary nail. Patients will be screened for eligibility and subgroupings. Informed consent will be obtained from those who meet screening criteria and are interested in participating in the study. Sites will be asked to enroll subjects according to past treatment, with the Fibulock™ intramedullary nail for unstable fibula fracture. The sites will enroll subjects in the study based on inclusion/exclusion criteria. Patient pre-operative, intra-operative and post-operative records will be reviewed retrospectively. Once enrolled, subjects will undergo an evaluation of fracture outcome and complete a VAS pain score, SF-12, and Foot Function Index at 26 weeks and again at 52 weeks post-treatment.
Interventions
DEVICEFibulock
Fibulock intramedullary implant will be used to repair fibula fractures
Sponsors
Arthrex, Inc.
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* An unstable fibula fracture. * Must be less than 31 weeks post-implantation * Must have received surgical treatment with the Fibulock Intramedullary Nail for their unstable fibula - fracture * Male or female greater than or equal to 18 years of age and skeletally mature. * Able to understand the requirements of the study, provide a written informed consent and comply with the study protocol * Ability to understand and provide written authorization for use and disclosure of personal health information.
Exclusion criteria
* Patients who are not implanted with a Sonoma Fibulock IM Nail
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy Assessment post implantation with Fibulock Intramedullary Nail assessed using lateral and mortice view x-rays | 26 weeks | Lateral and mortice view x-rays at 26 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analog Scale | 26 weeks and 52 weeks | Patient self reported pain intensity. |
| SF 12 | 26 weeks and 52 weeks | SF 12 is a Health Survey that uses just 12 questions to measure functional health and well-being from the patient's point of view. |
| Foot Function Index | 26 weeks and 52 weeks | The Foot Function Index (FFI) is used to measure the impact of foot pathology on function in terms of pain, disability and activity restriction. |
Countries
United States
Outcome results
None listed